New York State Teachers Retirement System held its position in shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 93,675 shares of the biotechnology company’s stock at the end of the first quarter. New York State Teachers Retirement System owned 0.14% of Momenta Pharmaceuticals worth $1,251,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also modified their holdings of the stock. Dynamic Technology Lab Private Ltd purchased a new stake in Momenta Pharmaceuticals during the first quarter worth approximately $158,000. BNP Paribas Arbitrage SA increased its stake in Momenta Pharmaceuticals by 13.3% in the first quarter. BNP Paribas Arbitrage SA now owns 13,393 shares of the biotechnology company’s stock worth $179,000 after buying an additional 1,570 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in Momenta Pharmaceuticals by 3.0% in the first quarter. Envestnet Asset Management Inc. now owns 14,275 shares of the biotechnology company’s stock worth $191,000 after buying an additional 411 shares during the last quarter. Municipal Employees Retirement System of Michigan increased its stake in Momenta Pharmaceuticals by 2.2% in the first quarter. Municipal Employees Retirement System of Michigan now owns 14,600 shares of the biotechnology company’s stock worth $195,000 after buying an additional 310 shares during the last quarter. Finally, Mason Street Advisors LLC increased its stake in Momenta Pharmaceuticals by 8.3% in the first quarter. Mason Street Advisors LLC now owns 15,122 shares of the biotechnology company’s stock worth $202,000 after buying an additional 1,154 shares during the last quarter. Institutional investors own 87.15% of the company’s stock.
Momenta Pharmaceuticals, Inc. (MNTA) traded down 1.54% during midday trading on Wednesday, reaching $16.00. 276,157 shares of the company traded hands. Momenta Pharmaceuticals, Inc. has a 12 month low of $10.66 and a 12 month high of $19.90. The firm’s market capitalization is $1.18 billion. The firm’s 50 day moving average price is $16.69 and its 200 day moving average price is $15.72.
Momenta Pharmaceuticals (NASDAQ:MNTA) last issued its earnings results on Wednesday, August 2nd. The biotechnology company reported ($0.50) earnings per share for the quarter, meeting the consensus estimate of ($0.50). Momenta Pharmaceuticals had a negative net margin of 39.35% and a negative return on equity of 12.28%. The business had revenue of $23.57 million for the quarter, compared to analyst estimates of $24.64 million. During the same period in the previous year, the business earned ($0.31) EPS. The firm’s revenue was down 10.8% on a year-over-year basis. On average, analysts expect that Momenta Pharmaceuticals, Inc. will post ($1.16) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: This report was first posted by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this report on another publication, it was stolen and reposted in violation of United States and international trademark and copyright law. The original version of this report can be viewed at https://stocknewstimes.com/2017/08/16/new-york-state-teachers-retirement-system-continues-to-hold-stake-in-momenta-pharmaceuticals-inc-mnta-updated-updated-updated.html.
A number of brokerages recently weighed in on MNTA. Stifel Nicolaus decreased their price target on shares of Momenta Pharmaceuticals from $30.00 to $26.00 and set a “buy” rating for the company in a research report on Wednesday, May 3rd. Aegis reaffirmed a “hold” rating and set a $17.00 price target on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 3rd. Maxim Group set a $6.00 price objective on shares of Momenta Pharmaceuticals and gave the company a “sell” rating in a research report on Wednesday, May 3rd. Cowen and Company reissued a “hold” rating and issued a $15.00 price objective on shares of Momenta Pharmaceuticals in a research report on Wednesday, May 3rd. Finally, Barclays PLC cut shares of Momenta Pharmaceuticals from an “overweight” rating to an “equal weight” rating and decreased their price objective for the company from $20.00 to $17.00 in a research report on Monday, May 22nd. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and two have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $16.63.
In related news, President Craig A. Wheeler sold 4,116 shares of Momenta Pharmaceuticals stock in a transaction dated Friday, May 19th. The shares were sold at an average price of $15.83, for a total transaction of $65,156.28. Following the completion of the transaction, the president now directly owns 281,919 shares of the company’s stock, valued at approximately $4,462,777.77. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Over the last quarter, insiders have sold 23,686 shares of company stock worth $393,741. 4.40% of the stock is owned by company insiders.
About Momenta Pharmaceuticals
Momenta Pharmaceuticals, Inc is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection).
Receive News & Ratings for Momenta Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Momenta Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
